Key result
Serum ANGPTL-3 concentrations were found to be an independent negative modulator of the cholesterol efflux capacity of HDL particles (standardized β=-0.172, p<0.05).
Why the study?
ANGPTL-3 modulates lipid metabolism and CAD risk via LPL suppression, but whether other mechanisms exist had not been elucidated.
Observational
Effect estimate: standardized β=-0.172
p-value: p=<0.05
ANGPTL-3 exhibits a negative modulatory function on cholesterol efflux capacity induced by HDL particles, providing a potential novel mechanism for its role in atherosclerosis.
No immediate clinical application for ANGPTL-3 testing; hypothesis-generating for HDL dysfunction in atherosclerosis and needs prospective validation.
BACKGROUND: Angiopoietin-like protein 3 (ANGPTL-3) modulates lipid metabolism and the risk of coronary artery disease (CAD), especially stable angina (SA), via suppressing lipoprotein lipase (LPL). However, whether there are other mechanisms is not elucidated yet. The current research explored the modulatory roles of ANGPTL-3 on high-density lipoprotein (HDL), which further affects atherosclerotic development. METHODS: -cholesterol loading THP-1 cell. RESULTS: The serum ANGPTL-3 levels presented no significant discordance between the SA group and the non-SA group, whereas the serum ANGPTL-3 levels in type 2 diabetes mellitus (T2DM) group were significantly elevated compared with those in the non-T2DM group [428.3 (306.2 to 736.8) ng/ml vs. 298.2 (156.8 to 555.6) ng/ml, p <0.05]. Additionally, the serum ANGPTL-3 levels were elevated in patients with low TG levels compared to those in patients with high TG levels [519.9 (377.6 to 809.0) ng/ml vs. 438.7 (329.2 to 681.0) ng/ml, p <0.05]. By comparison, the individuals in the SA group and T2DM group presented decreased cholesterol efflux induced by HDL particles [SA: (12.21±2.11)% vs. (15.51±2.76)%, p <0.05; T2DM: (11.24±2.13)% vs. (14.65± 3.27)%, p <0.05]. In addition, the serum concentrations of ANGPTL-3 were inversely associated with the cholesterol efflux capacity of HDL particles (r=-0.184, p <0.05). Through regression analysis, the serum concentrations of ANGPTL-3 were found to be an independent modulator of the cholesterol efflux capacity of HDL particles (standardized β=-0.172, p <0.05). CONCLUSION: ANGPTL-3 exhibited a negative modulatory function on cholesterol efflux capacity induced by HDL particles.
No takes yet. Share an insight, caveat, or question.
Lai et al. (2023) conducted an observational in Stable angina and type 2 diabetes mellitus. Serum ANGPTL-3 levels was evaluated on Cholesterol efflux capacity of HDL particles (standardized β=-0.172, p=<0.05). Serum ANGPTL-3 concentrations were found to be an independent negative modulator of the cholesterol efflux capacity of HDL particles (standardized β=-0.172, p<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: